Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

ABSTRACT:

Background

Open-label 15-month follow-up of the double-blind, placebo-controlled Glatiramer Acetate clinical Trial to assess Equivalence with Copaxone^® (GATE) trial.

Objective

To evaluate efficacy, safety, and tolerability of prolonged generic glatiramer acetate (GTR) treatment and to evaluate efficacy, safety, and tolerability of switching from brand glatiramer acetate (GA) to GTR treatment.

Methods

A total of 729 patients received GTR 20 mg/mL daily. Safety was assessed at months 12, 15, 18, 21, and 24 and Expanded Disability Status Scale and magnetic resonance imaging (MRI) scans at months 12, 18, and 24. The presence of glatiramer anti-drug antibodies (ADAs) was tested at baseline and months 1, 3, 6, 9, 12, 18, and 24.

Results

The mean number of

SUBMITTER: Selmaj K 

PROVIDER: S-EPMC5700775 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature